Related Experiment Videos
New agent development for women with breast cancer
1University of Texas Health Science Center at San Antonio, USA.
Cancer Investigation
|January 1, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Cancer chemotherapy and pharmacology·2014
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
European journal of cancer (Oxford, England : 1990)·2012
Telomerase and telomere inhibitors in preclinical development.
Expert opinion on investigational drugs·2005
Exosome therapy for knee osteoarthritis: a network meta-analysis based on rat models.
Stem cells translational medicine·2026
Tobacco and Marijuana Induce Adverse Effects on Cardiac Function and Platelet Activity and Reduce Tissue Preservation Following Myocardial Infarction.
American journal of physiology. Heart and circulatory physiology·2026
Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.
British journal of haematology·2026